Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies

Area of Science:

• Genomics
• Oncology
• Molecular Diagnostics

Background:

• Somatic mutations and copy number aberrations are crucial for understanding myeloid neoplasms.
• Current methods like karyotype and FISH have limitations in resolution and scope.
• Accurate genetic assessment is vital for cancer pathogenesis and patient management.

Purpose of the Study:

• To review the clinical significance of Chromosomal Microarray (CMA) in myeloid neoplasms.
• To highlight CMA's advantages over conventional methods for copy number assessment.
• To discuss scenarios where CMA can alter treatment and management.

Main Methods:

• Review of current literature on Chromosomal Microarray (CMA) in myeloid malignancies.
• Analysis of CMA's diagnostic, prognostic, and therapeutic utility.
• Comparison of CMA with conventional karyotyping and FISH.

Main Results:

• CMA provides high-resolution characterization of chromosomal aberrations and copy-neutral loss of heterozygosity (CN-LOH).
• CMA results complement next-generation sequencing (NGS) mutation studies.
• CN-LOH, a prognostic marker in AML, is uniquely identified by CMA.

Conclusions:

• CMA is an effective technology for high-resolution genetic analysis in myeloid malignancies.
• Despite its benefits, CMA is underutilized due to a lack of standardized testing practices.
• Implementing CMA can provide essential information for managing AML, MDS, and MDS/MPN.